Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
about
68Ga-Based radiopharmaceuticals: production and application relationshipSurgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentPeptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experienceGene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors.PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.Preparation of a versatile bifunctional zeolite for targeted imaging applicationsEffect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.Ectopic ACTH and CRH Co-secreting Tumor Localized by 68Ga-DOTA-TATE PET/CTMeasured human dosimetry of 68Ga-DOTATATE.A multimodal approach to the management of neuroendocrine tumour liver metastasesTalc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT.Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumorsEANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.Lutetium DOTATATE whole body scans: A novel approach for evaluation of neuroendocrine tumors.(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2The Synthesis and Evaluations of the (6 8) Ga-Lissamine Rhodamine B (LRB) as a New Radiotracer for Imaging Tumors by Positron Emission Tomography.Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursProspective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary SitesGa-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in IndiaGastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementFree somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.Prospective of ⁶⁸Ga-radiopharmaceutical development.Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Role of PET/CT in the functional imaging of endocrine pancreatic tumors.Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.
P2860
Q26801794-E8C76EC2-0B64-4C24-BF32-DECEBDEB3E0CQ27026980-1412B302-BFAE-40CE-8CA7-F3716D319647Q28071483-AA485703-6768-4DBB-8D95-059E6B89064FQ28083433-0B9486B4-A2A6-4557-8D74-81D1E6FB3C06Q33397018-CB539EEF-B69E-4DCA-9E56-FD24E884D2D8Q33403035-F4B9167F-A014-4B8B-B5AD-AB9BD6CB40E7Q34012005-49A348A8-BD21-4232-AD12-F65FF9ECC60AQ34682187-CF438ACF-2AD5-45B9-A04B-83EAD6D39F4AQ34696158-0C498B21-3C14-40C6-BBC1-E71EE8195427Q35038168-58C0241C-949B-4D9B-B33A-4FA3234FB2B5Q35550939-BEBBE08F-D281-4B64-9A2E-5DFA115DCB1EQ35650633-812E1CAA-D26C-4E6C-9F48-1EAAF0D266FEQ35695753-E2AFB8E2-D4F1-408F-9367-9AE2D9A60467Q35756123-4E588F9D-1E7E-4A23-B6A2-BEA930188297Q35810562-20F020BF-AAE3-44FC-8366-4138C77363A2Q36042311-592BB59B-3B51-4B45-A813-574F96BEC790Q36149338-158F2C5E-41F6-4CC5-9ACF-4B6C080C2E17Q36157472-F5AB4A96-41C9-4669-8B0F-87350EEFB757Q36322884-B4B6907B-AD63-4863-9FD8-8D0641B8B2E6Q36467722-DF65A7A4-E847-4D76-877C-317F06783A63Q36527769-FCDC8D87-CC8D-4C18-95A3-A0EDEE3D7B63Q36568335-0301A8E2-55F0-433D-941C-83FD94B1374FQ36582609-EC341B91-F491-45C1-A731-083C74B2F1EBQ36661451-851CBC85-0246-4FE0-A3DC-8B817D7DED87Q36755905-29426594-081E-4D96-BECF-9D1B41D6FE32Q36914468-CDFE172D-2F06-4AFB-BF9E-F58D9CBA91EAQ36936960-0F842179-360E-4442-A380-753C72B1D45BQ37017018-87254A04-6813-4BA7-A92F-519ED0462431Q37302087-43117F75-2F60-4D14-AE97-9F380613883EQ37365221-1FD47317-A06E-4001-80FF-A83B76D582B1Q37435222-127884A8-6F46-42F4-9657-E202A3CE7EAFQ37504159-F1E0BE9E-853D-4580-B409-0AC96279772FQ37592451-923045A9-BC1D-4D3A-AA09-E67FEDA8C709Q37962416-C0EE9AEA-A332-497B-A4E6-FA453EC6D29DQ37990397-B0866251-6BE6-4E23-8D61-EBB5ADEF84EFQ37990403-15301CA0-3C28-4AD3-A526-FBC1BEF66B1BQ37994083-712EAE7F-1ED6-4D67-AD82-B7C96BDE9A19Q38036127-3D692C32-A505-4C9D-A3A8-970EAD8861CCQ38123057-C3026A3B-395D-43E1-B7E6-DCFD11EB12FFQ38127505-C9553F05-7C51-4A7E-8AD5-678809834D9D
P2860
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@en
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@nl
type
label
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@en
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@nl
prefLabel
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@en
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
@nl
P2093
P50
P1476
Procedure guidelines for PET/C ...... 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
@en
P2093
Clemens De Cristoforo
Irene Virgolini
Jamshed B Bomanji
Michael Gabriel
Nikolaos D Papathanasiou
Richard P Baum
Stefano Fanti
P2860
P2888
P304
P356
10.1007/S00259-010-1512-3
P577
2010-10-01T00:00:00Z